H.C. Wainwright lowered the firm’s price target on Annexon (ANNX) to $14 from $20 and keeps a Buy rating on the shares. The firm reduced the stock’s multiple and increased its discount rates to better align with current investor sentiment, elevated cost of capital, and reduced appetite for early-stage clinical risk. Annexon announced that it is on track to meet with the FDA for tanruprubart around Q2, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon Biosciences: Promising Growth Potential with Key Catalysts and Strategic FDA Interactions
- Annexon Biosciences: Buy Rating Driven by Regulatory Milestones and Promising Pipeline Developments
- Annexon Biosciences Reports Increased Q1 2025 Losses
- Annexon reports Q1 EPS (37c), consensus (29c)
- Annexon sees cash runway into 2H26
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue